Ontology highlight
ABSTRACT:
SUBMITTER: Kim D
PROVIDER: S-EPMC6494839 | biostudies-other | 2019 May
REPOSITORIES: biostudies-other
Cell death & disease 20190501 5
Acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has been a major obstacle in the treatment of non-small cell lung cancer (NSCLC) patients. AXL has been reported to mediate EGFR-TKIs. Recently, third generation EGFR-TKI osimertinib has been approved and yet its acquired resistance mechanism is not clearly understood. We found that AXL is involved in both gefitinib and osimertinib resistance using in vitro and in vivo model. In addition, AXL overexpre ...[more]